We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Serum and CSF Biomarkers Predict Active Early Cognitive Decline Rather Than Established Cognitive Impairment at the Moment of RRMS Diagnosis.
- Authors
Tiu, Vlad Eugen; Popescu, Bogdan Ovidiu; Enache, Iulian Ion; Tiu, Cristina; Terecoasa, Elena; Panea, Cristina Aura
- Abstract
(1) Background: Cognitive impairment (CI) begins early in the evolution of multiple sclerosis (MS) but may only become obvious in the later stages of the disease. Little data is available regarding predictive biomarkers for early, active cognitive decline in relapse remitting MS (RRMS) patients. (2) Methods: 50 RRMS patients in the first 6 months following diagnosis were included. The minimum follow-up was one year. Biomarker samples were collected at baseline, 3-, 6- and 12-month follow-up. Cognitive performance was assessed at baseline and 12-month follow-up; (3) Results: Statistically significant differences were found for patients undergoing active cognitive decline for sNfL z-scores at baseline and 3 months, CSF NfL baseline values, CSF Aβ42 and the Bremso score as well. The logistic regression model based on these 5 variables was statistically significant, χ2(4) = 22.335, p < 0.0001, R2 = 0.671, with a sensitivity of 57.1%, specificity of 97.4%, a positive predictive value of 80% and a negative predictive value of 92.6%. (4) Conclusions: Our study shows that serum biomarkers (adjusted sNfL z-scores at baseline and 3 months) and CSF biomarkers (CSF NfL baseline values, CSF Aβ42), combined with a clinical score (BREMSO), can accurately predict an early cognitive decline for RRMS patients at the moment of diagnosis.
- Subjects
COGNITION disorders; DIAGNOSIS; BIOMARKERS; LOGISTIC regression analysis; COGNITIVE ability
- Publication
Diagnostics (2075-4418), 2022, Vol 12, Issue 11, p2571
- ISSN
2075-4418
- Publication type
Article
- DOI
10.3390/diagnostics12112571